Posted by Reporter on Thursday
http://www.dailywebtv.com/Halton/video/11372 - If you’re tired of waxing and shaving, a relatively new treatment for hair removal may be the answer. Using a state-of-the-art laser process, the staff at California Laser Skin Care in Burlington has helped their clients get rid of unwanted hair permanently.
“The laser heats up the follicle during a process called selective photothermolysis, which uses optical energy and radio frequency,” said Melisa Mariutti from California Laser Skin Care.
0 views | 0 comments
Click here to watch the video (04:58)
Submitted By: dailywebtv
Tags:
An Effective Way To Remove Unwanted Hair California Lasers Skin Care
Categories: Science & Tech
Go to source
Posted by Reporter on
http://www.dailywebtv.com/Halton/video/11371 - Changes in skin tone, sagging skin and wrinkles are all tell-tale signs of an aging face. At California Laser Skin Care Clinics, a new laser treatment is helping to reverse those signs by helping the body stimulate its own repairs.
“We have a Trinity treatment that treats the three different skin problems in one treatment.” said Emily DeNardis of California Laser Skin Care Clinics. “It tightens the skin by stimulating the body to reproduce collagen; it will correct some of the red, spider veins and brown spots; and it’s an advanced wrinkle treatment.”
1 views | 0 comments
Click here to watch the video (05:06)
Submitted By: dailywebtv
Tags:
New Treatments To Combat Signs Aging Lasers Trinity
Categories: Science & Tech
Go to source
Posted by Reporter on
New clinical research proves effectiveness of Boots No7 Refine & Rewind Intense Perfecting Serum.
1 views | 0 comments
Click here to watch the video (01:35)
Submitted By: cnwgroup
Tags:
Boots No7 Refine Rewind Anti-aging Cosmetic Beauty Products Skin Care Fibrillin Serum
Categories: News & Events
Go to source
Posted by Reporter on
Solta Medical, Inc. is proud to celebrate the launch of the new Thermage CPT and Fraxel re:store Dual systems with the kick off of the illumiNATION tour (www.illumiNATIONtour.com). Starting September 14 and continuing through November, the illumiNATION tour is bringing the latest breakthroughs in Thermage and Fraxel systems directly to physicians in over 20 cities across the U.S. and 11 cities in Europe.
The tour will travel from city-to-city aboard a classic - but modernized - Airstream trailer outfitted with Thermage and Fraxel treatment stations. The sleek, iconic Airstream continues to be celebrated for its eye-catching, innovative design and remains the epitome of style and glamour on the road. Solta Medical is bringing that same timeless yet modern style and beauty to major U.S. and European cities to demonstrate how these new treatments can help you look younger and feel fabulous without the need for invasive procedures.
“We are delighted to be among the first practices in the world to adopt the latest systems from Solta Medical,” said Neil Sadick, MD, Clinical Professor of Dermatology, Weill Cornell Medical College. “The illumiNATION tour will generate significant awareness of these exciting new Thermage and Fraxel procedures in every city that it visits.”
The tour kicks off in Chicago on September 14 & 15 and travels throughout the U.S. and Europe in October and November. Appointments are available for physicians and their staff to evaluate the new Thermage and Fraxel systems. To find out when the tour will be near you, go to www.illuminationtour.com and click the “Join Us” tab.
“The new Thermage CPT and Fraxel re:store Dual systems represent the next generation of anti-aging treatments and are now better than ever for skin tightening and skin resurfacing,” said Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical, Inc. “I am confident these innovative new products will change the way people think about aesthetic procedures. We believe such breakthrough systems deserve a unique introduction to the market, and the illumiNATION tour is the first of its kind in the aesthetic industry.”
About the Thermage CPT system
The Thermage CPT system represents a leap forward in skin tightening and body contouring technology. The Thermage CPT incorporates proprietary Comfort Pulse Technology(TM), along with a breakthrough vibrating handpiece, to offer the maximum in treatment efficacy and patient comfort. Thermage is the premier non-invasive procedure to help tighten and contour skin in a single treatment with no surgery, no injections and little to no downtime.
About the Fraxel re:store Dual system
The new non-ablative Fraxel re:store Dual system takes the industry leading Fraxel technology to the next level by adding a novel 1927 nm wavelength, the first-ever application of a Thulium laser in the aesthetics market. The new wavelength enables physicians to treat multiple body areas in one treatment session and better address pigmentation and other dyschromia with minimal discomfort.
ShareThis
Go to source
Posted by Reporter on
NovaBay Pharmaceuticals, Inc., (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide compound NVC-422 in impetigo.
NovaBay’s partner in the impetigo trial is Galderma, S.A. the world’s leading dermatology company. NovaBay also is currently engaged in clinical studies of NVC-422 for viral conjunctivitis with its other major partner Alcon, the world’s leading eye care company.
This double blind, randomized, sequential group study will evaluate the safety and efficacy of a dermal formulation of NVC-422 in 120 patients ages 2 to 12 at two experienced clinical centers in the Dominican Republic. Over 15 patients have been enrolled so far and final results are expected in the first half of 2010.
Impetigo is one of the most common bacterial skin infections affecting over one million people in the US alone, primarily infants and children between the ages of two and six.(1) Impetigo usually starts with direct bacterial invasion of healthy skin or when bacteria enter a break in the skin, such as a cut, scratch or insect bite. Symptoms begin with red or pimple-like sores surrounded by red skin. These sores usually occur on the face, arms and legs and fill with pus, then break open after a few days and form a thick crust. Impetigo can spread by contact with sores or nasal discharge from an infected
person.(2)
“Currently impetigo is treated with antibiotic ointments, to which bacteria develop resistance in the same way as to oral antibiotics. An effective alternative treatment for such a common skin disease could significantly reduce our over-reliance on antibiotics and help stop the global spread of drug-resistant bacteria,” said Ron Najafi, Ph.D., Chairman and Chief Executive Officer, NovaBay. “Our goal at NovaBay is to make the need for all topical antibiotics obsolete with our Aganocide compounds, which have no known mechanism for inducing microbial resistance.”
Impetigo is primarily caused by Staphylococcus aureus and Streptococcus pyogenes. The skin condition typically is not life-threatening, but sometimes it may lead to serious complications, including(3):
- Methicillin-resistant Staphylococcus aureus (MRSA) infection, which can cause serious skin infections that are extremely difficult to treat.
- Post-streptococcal glomerulonephritis, which is a kidney inflammation that may lead to chronic kidney failure.
- Cellulitis, which is a potentially serious infection that affects the tissues underlying the skin and eventually may spread to the lymph nodes and into the bloodstream.
About Aganocide Compounds
The Aganocide compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay to mimic the body’s natural defense against infection. The Aganocide compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated,
first-in-class, small-molecule, patented new chemical entities may be able to deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial strains. In preclinical testing, the Aganocide compounds have been shown to be highly effective against bacteria, including multi-drug resistant strains, viruses and fungi. They also have been demonstrated to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a broad therapeutic index while providing a high degree of potency and
tolerability as well as dosing versatility and flexibility.
About NovaBay
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic, anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing dermatological, hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com.
(1) http://findarticles.com/p/articles/mi_m0816/is_n5_v9/ai_6741369/
(2) http://www.nlm.nih.gov/medlineplus/impetigo.html
(3) http://www.mayoclinic.com/print/impetigo/DS00464/DSECTION=all&METHOD=print
ShareThis
Go to source
